Petros Pharmaceuticals (NASDAQ:PTPI) Shares Down 5.8% – What’s Next?

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)’s stock price traded down 5.8% on Friday . The stock traded as low as $0.32 and last traded at $0.33. 6,130,722 shares were traded during trading, an increase of 1,045% from the average session volume of 535,337 shares. The stock had previously closed at $0.35.

Petros Pharmaceuticals Stock Performance

The company has a fifty day moving average of $0.32 and a two-hundred day moving average of $0.37. The firm has a market capitalization of $3.30 million, a price-to-earnings ratio of -0.07 and a beta of 1.99. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.74 and a current ratio of 0.85.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).